These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37286927)

  • 21. Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine.
    Houts CR; Wirth RJ; McGinley JS; Cady R; Lipton RB
    Headache; 2020 Oct; 60(9):2003-2013. PubMed ID: 32862469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re-examining the factor structure of the Insomnia Severity Index (ISI) and defining the meaningful within-individual change (MWIC) for subjects with insomnia disorder in two phase III clinical trials of the efficacy of lemborexant.
    Lenderking WR; Savva Y; Atkinson MJ; Campbell R; Chabot I; Moline M; Meier G; Morin CM
    J Patient Rep Outcomes; 2024 Jun; 8(1):65. PubMed ID: 38951287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
    Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
    Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.
    Walsh JK; Krystal AD; Amato DA; Rubens R; Caron J; Wessel TC; Schaefer K; Roach J; Wallenstein G; Roth T
    Sleep; 2007 Aug; 30(8):959-68. PubMed ID: 17702264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial.
    Dauvilliers Y; Verbraecken J; Partinen M; Hedner J; Saaresranta T; Georgiev O; Tiholov R; Lecomte I; Tamisier R; Lévy P; Scart-Gres C; Lecomte JM; Schwartz JC; Pépin JL;
    Am J Respir Crit Care Med; 2020 May; 201(9):1135-1145. PubMed ID: 31917607
    [No Abstract]   [Full Text] [Related]  

  • 26. Insomnia and sleepiness in Parkinson disease: associations with symptoms and comorbidities.
    Chung S; Bohnen NI; Albin RL; Frey KA; Müller ML; Chervin RD
    J Clin Sleep Med; 2013 Nov; 9(11):1131-7. PubMed ID: 24235893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ecological momentary assessment of daytime symptoms during sleep restriction therapy for insomnia.
    Miller CB; Kyle SD; Marshall NS; Espie CA
    J Sleep Res; 2013 Jun; 22(3):266-72. PubMed ID: 23331712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral Appliance Therapy in Patients With Daytime Sleepiness and Snoring or Mild to Moderate Sleep Apnea: A Randomized Clinical Trial.
    Marklund M; Carlberg B; Forsgren L; Olsson T; Stenlund H; Franklin KA
    JAMA Intern Med; 2015 Aug; 175(8):1278-85. PubMed ID: 26030264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychometric Evaluation of a New Patient-Reported Outcome (PRO) Symptom Diary for Varicose Veins: VVSymQ(®) Instrument.
    Wright DD; Paty J; Turner-Bowker DM; Bradbury A
    Patient; 2016 Aug; 9(4):335-48. PubMed ID: 27016239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.
    Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T
    Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.
    Gottlieb AB; Warren RB; Augustin M; Garcia L; Cioffi C; Peterson L; Pelligra C; Ciaravino V
    Adv Ther; 2021 Oct; 38(10):5253-5269. PubMed ID: 34471992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials.
    Jiang F; Li H; Chen Y; Lu H; Ni J; Chen G
    Medicine (Baltimore); 2023 Feb; 102(7):e32754. PubMed ID: 36800596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meaningful Change Thresholds and Fatigue Severity Points on Patient-Reported Outcomes by the Fatigue Symptoms and Impacts Questionnaire in Patients With Relapsing Multiple Sclerosis.
    Hudgens S; Katz EG; Davies E; Keenan A; Sidorenko T; Jamieson C
    Value Health; 2024 May; 27(5):598-606. PubMed ID: 38401796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sham sleep feedback delivered via actigraphy biases daytime symptom reports in people with insomnia: Implications for insomnia disorder and wearable devices.
    Gavriloff D; Sheaves B; Juss A; Espie CA; Miller CB; Kyle SD
    J Sleep Res; 2018 Dec; 27(6):e12726. PubMed ID: 29989248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daytime symptoms in primary insomnia: a prospective analysis using ecological momentary assessment.
    Buysse DJ; Thompson W; Scott J; Franzen PL; Germain A; Hall M; Moul DE; Nofzinger EA; Kupfer DJ
    Sleep Med; 2007 Apr; 8(3):198-208. PubMed ID: 17368098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of suanzaoren decoction for chronic insomnia disorder in adults: study protocol for randomised, double-blind, double-dummy, placebo-controlled trial.
    Zhou QH; Wang HL; Zhou XL; Xu MB; Zhang HF; Huang LB; Zheng GQ; Lin Y
    BMJ Open; 2017 Apr; 7(4):e014280. PubMed ID: 28377394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sleep disturbances in the elderly residing in assisted living: findings from the Maryland Assisted Living Study.
    Rao V; Spiro JR; Samus QM; Rosenblatt A; Steele C; Baker A; Harper M; Brandt J; Mayer L; Rabins PV; Lyketsos CG
    Int J Geriatr Psychiatry; 2005 Oct; 20(10):956-66. PubMed ID: 16163747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
    Chepke C; Jain R; Rosenberg R; Moline M; Yardley J; Pinner K; Kumar D; Perdomo C; Filippov G; Atkins N; Malhotra M
    Postgrad Med; 2022 Apr; 134(3):316-325. PubMed ID: 35254948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the sleep impact scale in patients with major depressive disorder and insomnia.
    Lasch K; Joish VN; Zhu Y; Rosa K; Qiu C; Crawford B
    Curr Med Res Opin; 2009 Jul; 25(7):1699-710. PubMed ID: 19505198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.